139 related articles for article (PubMed ID: 25999240)
1. Tracing the footprints of the breast cancer oncogene BRK - Past till present.
Goel RK; Lukong KE
Biochim Biophys Acta; 2015 Aug; 1856(1):39-54. PubMed ID: 25999240
[TBL] [Abstract][Full Text] [Related]
2. Putting the BRK on breast cancer: From molecular target to therapeutics.
Ang HL; Yuan Y; Lai X; Tan TZ; Wang L; Huang BB; Pandey V; Huang RY; Lobie PE; Goh BC; Sethi G; Yap CT; Chan CW; Lee SC; Kumar AP
Theranostics; 2021; 11(3):1115-1128. PubMed ID: 33391524
[TBL] [Abstract][Full Text] [Related]
3. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
4. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
6. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Jiang J; Gui F; He Z; Li L; Li Y; Li S; Wu X; Deng Z; Sun X; Huang X; Huang W; Han S; Zhang T; Wang Z; Jiao B; Song S; Wang H; Chen L; Zhou D; Liu Q; Ren R; Zhang J; Deng X
Cancer Res; 2017 Jan; 77(1):175-186. PubMed ID: 27758886
[TBL] [Abstract][Full Text] [Related]
8. Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets.
Sahu R; Pattanayak SP
Curr Gene Ther; 2020; 20(4):237-258. PubMed ID: 32807051
[TBL] [Abstract][Full Text] [Related]
9. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Goel RK; Lukong KE
Cancer Metastasis Rev; 2016 Jun; 35(2):179-99. PubMed ID: 27067725
[TBL] [Abstract][Full Text] [Related]
10. Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y; Specht S; Isse K; Sasatomi E; Lunz JG; Takizawa T; Demetris AJ
J Hepatol; 2015 Aug; 63(2):399-407. PubMed ID: 25770659
[TBL] [Abstract][Full Text] [Related]
11. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Brauer PM; Tyner AL
Biochim Biophys Acta; 2010 Aug; 1806(1):66-73. PubMed ID: 20193745
[TBL] [Abstract][Full Text] [Related]
12. Brk is coamplified with ErbB2 to promote proliferation in breast cancer.
Xiang B; Chatti K; Qiu H; Lakshmi B; Krasnitz A; Hicks J; Yu M; Miller WT; Muthuswamy SK
Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12463-8. PubMed ID: 18719096
[TBL] [Abstract][Full Text] [Related]
13. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.
Harvey AJ; Crompton MR
Oncogene; 2003 Aug; 22(32):5006-10. PubMed ID: 12902983
[TBL] [Abstract][Full Text] [Related]
14. Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk.
Mitchell PJ; Barker KT; Shipley J; Crompton MR
Oncogene; 1997 Sep; 15(12):1497-502. PubMed ID: 9333026
[TBL] [Abstract][Full Text] [Related]
15. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
[TBL] [Abstract][Full Text] [Related]
16. BRK tyrosine kinase expression in a high proportion of human breast carcinomas.
Barker KT; Jackson LE; Crompton MR
Oncogene; 1997 Aug; 15(7):799-805. PubMed ID: 9266966
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
18. Identification of STAT3 as a specific substrate of breast tumor kinase.
Liu L; Gao Y; Qiu H; Miller WT; Poli V; Reich NC
Oncogene; 2006 Aug; 25(35):4904-12. PubMed ID: 16568091
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the cell cycle by breast tumor kinase (Brk).
Chan E; Nimnual AS
Int J Cancer; 2010 Dec; 127(11):2723-31. PubMed ID: 20162673
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
